Skip to main content
Fig. 1 | EJNMMI Research

Fig. 1

From: Synthesis and preclinical evaluation of novel 99mTc-labeled PSMA ligands for radioguided surgery of prostate cancer

Fig. 1

Molecular structures of the novel N4-PSMA ligands were derived from rhPSMA-7.3 by substitution of (S)-DOTAGA with a tetraamine (N4) chelator for complexation of technetium-99m (indicated in green) and incorporation of a less lipophilic, hydrolized derivative of the silicon fluoride acceptor-moiety (indicated in blue). A variable amino acid (X, red) is introduced in N4-PSMA-12, N4-PSMA-13 and N4-PSMA-21 to modulate their pharmacokinetic properties

Back to article page